Scienture Holdings, Inc. (NASDAQ: SCNX) holds existing and planned pharmaceutical operating companies. Focused on providing enhanced value to patients, physicians, and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs.
Scienture, LLC is a New York-based pharmaceutical company driven by a highly experienced team passionate about developing unique specialty products that bring enhanced value to patients and healthcare systems.
SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.
